Corporate Banner
Satellite Banner
Crystallography
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

A New EU-Funded Industry-Academia Drug Discovery Partnership Targets Challenging Kinases

Published: Wednesday, April 10, 2013
Last Updated: Wednesday, April 10, 2013
Bookmark and Share
Industry and academia join to create the Translational Kinase Tumor Inhibitor Discovery Consortium.

SARomics Biostructures, Prestwick Chemical and ProQinase together with the University of Turin, Italy, the Israel Structural Proteomics Center (ISPC) at the Weizmann Institute of Science, Israel, and the TechMedIll platform of the University of Strasbourg, France, announce that they have created the Translational Kinase Tumor Inhibitor Discovery Consortium (TAKTIC), funded with €1.1 million by the EU 7th Framework Program “Research for the Benefit of SMEs”.

Targeting kinases has become one of the most important therapeutic opportunities for treating cancer, diabetes, inflammatory diseases and more. The TAKTIC Consortium brings together the unique and proprietary technologies of three SMEs and their knowhow in the field of drug discovery. To this are coupled the extensive expertise in medicinal chemistry, kinase biochemistry and biology of the University of Turin as well as the state-of-the-art high throughput platform for protein expression and crystallization of the Israel Structural Proteomics Centre. The merging of the highly complementary capabilities of the six partners within the TAKTIC Consortium enables an efficient and versatile kinase drug discovery platform that will target some challenging and medically important kinases.

“We are excited to coordinate a frontline project of these dimensions, which brings together companies and academic researchers with impressive track records within their respective fields.” says Prof. Salam Al-Karadaghi, project coordinator and Director of Business Development at SARomics Biostructures.

“This exciting project fits with our corporate strategy to generate future value through collaborations with top-tiered SMEs and academic groups” added Prof. Thierry Langer, CEO at Prestwick.

“ProQinase is very pleased to join this attractive project since it brings together complementary expertise from biotech industry and academia creating highly promising synergies in the development of novel anti-cancer drugs” explained Christoph Schächtele, Managing Director of ProQinase.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

SARomics Biostructures and Xbrane Bioscience Form a Strategic Partnership
Strategic partnership to deliver “off-the-shelf” protein structure services.
Thursday, January 30, 2014
SARomics Biostructures and Red Glead Discovery Enters into Drug Discovery Collaboration
The companies will perform a joint collaborative project with the goal of developing novel lead compounds against epigenetic pathway targets.
Thursday, October 25, 2012
SARomics Biostructures Brings in New Strategic Owners
Innovationsbron AB and LUIS AB are investing in and becoming new co-owners of the company.
Saturday, September 15, 2012
Scientific News
Neutron Analysis of HIV-1 Protease
Neutrons probe structure of enzyme critical to development of next-generation HIV drugs.
Do Germs Cause Type 1 Diabetes?
Germs could play a role in the development of type 1 diabetes by triggering the body’s immune system to destroy the cells that produce insulin, new research suggests.
Crucial Reaction for Vision Revealed
Scientists have tracked the reaction of a protein responding to light, paving the way for a new understanding of life's essential reactions.
Secrets of a Deadly Virus Family Revealed
Scripps Research scientists uncover the glycoprotein structure of LCMV. The findings could guide development of treatments for Lassa fever.
Serotonin Transporter Structure Revealed
Researchers determined the 3-D structure of the serotonin transporter and visualized how two common antidepressants interact with the protein.
Zika Virus Structure Revealed
Team at Purdue becomes the first to determine the structure of the Zika virus, which reveals insights critical to the development of effective antiviral treatments and vaccines.
Half a Million-Dollar Tick
How proteins present in tick saliva prevent the immune system from running amok.
Promising Model for Hantavirus Drug Design
X-ray crystallography provides drug template against disease transmitted by small rodents.
A Crystal Clear View of Biomolecules
Fundamental discovery triggers paradigm shift in crystallography.
'Molecular Movie' Opens Door to New Cancer Treatments
An international team of scientists led by the University of Liverpool has produced a 'structural movie' revealing the step-by-step creation of an important naturally occurring chemical in the body that plays a role in some cancers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!